Dressel Alexander, Vogelgesang Antje, Brinkmeier Heinrich, Mäder Michael, Weber Frank
Department of Neurology, Ernst Moritz Arndt University Greifswald, Sauerbruchstr., 17489 Greifswald, Germany.
J Neuroimmunol. 2006 Dec;181(1-2):133-40. doi: 10.1016/j.jneuroim.2006.07.014. Epub 2006 Nov 7.
Glatiramer acetate (GA) is an approved drug for therapy of relapsing remitting MS that acts as a T cell antigen. Here, we report the cloning of HLA restricted, GA-specific human CD8(+) T cells. In addition, we analyzed the cytokine profile of GA-reactive CD8(+) T cell lines. Unexpectedly, IL-4 was increased in untreated MS patients as compared to healthy individuals (p<0.001). In GA-treated patients, however, IL-4 (p<0.001), IL-10 (p<0.001) and TNF-alpha (p<0.001) were decreased. Thus, while GA is known to induce a TH2 bias in CD4(+) T cells, we detected a distinct pattern in GA-reactive CD8(+) T cells.
醋酸格拉替雷（GA）是一种已获批准用于治疗复发缓解型多发性硬化症的药物，它作为一种T细胞抗原发挥作用。在此，我们报告了HLA限制的、GA特异性人类CD8(+) T细胞的克隆。此外，我们分析了GA反应性CD8(+) T细胞系的细胞因子谱。出乎意料的是，与健康个体相比，未经治疗的多发性硬化症患者体内的IL-4有所增加（p<0.001）。然而，在接受GA治疗的患者中，IL-4（p<0.001）、IL-10（p<0.001）和TNF-α（p<0.001）均有所下降。因此，虽然已知GA会在CD4(+) T细胞中诱导TH2偏向，但我们在GA反应性CD8(+) T细胞中检测到了一种不同的模式。
